Transasia Bio-Medicals brings its
international hematology range backed by European R&D to Indian market
The
Erba Hematology range will expand mass access to high-quality diagnostics, making
it more affordable for adoption of automated hematology testing by
labs across India
Transasia Bio-Medicals Ltd., India's No. 1 In-vitro Diagnostic (IVD) Company and among
the leading global players globally focused on emerging markets, today
announced that it is bringing its international hematology range for the first
time to Indian market. Backed by European R&D, the 3-Part Differential
(3PD) to 5-Part Differential (5PD) fully automated hematology analyzers,
reagents and controls will be commercially launched from April 1, 2019 across
India. These next-generation instruments include a number of features to help
institutions, clinicians and laboratory technologists offer accurate diagnosis.
Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in Europe,
the H 360, H 560 and ELite 580 hematology analyzers are widely used in the
European market. Hematology analyzers are extensively used in patient and
research settings to count and characterize blood cells for disease detection
and monitoring. Basic analyzers return a complete blood count (CBC)
with a three-part differential white blood cell (WBC) count. Sophisticated
analyzers measure cell morphology and can detect small cell populations to
diagnose rare blood conditions.
Formally
introducing the range, Suresh Vazirani,
Chairman & Managing Director, Transasia Bio-Medicals
Ltd., said, “Today marks a major
milestone in our quest to make high quality diagnostics affordable for the
masses in India. The international hematology range that we are introducing in
India is comparable to the best in the world. Which means that the more these
equipment penetrate the Indian market, the more affordable and accessible will
be such basic tests for the larger population. This really moves the needle on
better preventive healthcare in India, over the long-term. It is a proud moment
for all of us at Transasia and it is apt that this coincides with the completion
of Transasia’s 40th anniversary celebration.”
Added Mala Vazirani, Executive Director, Transasia Bio-Medicals Ltd., “Eastern region is the most loyal market and among the fastest growing markets for Transasia in India. West Bengal is the largest market for us in this region constituting 8% of our national revenues. The new hematology range will be of relevance to West Bengal and eastern region which has unique and high incidence of hemoglobinopathies like Thalassemia, sickle cell anemia besides others. It always gives us immense satisfaction to be able to make a difference to the masses through accurate diagnostics which is affordable.”
As per a 2018
Union Ministry of Health and Family Welfare study, India has the largest number
of children with Thalassemia major in the world (150,000). There are almost 42
million carriers of β- thalassemia trait. While the prevalence averages 3-4% across
India, a higher frequency has been observed in certain communities, such as Sindhis,
Punjabis, Gujaratis, Bengalis, Mahars, Kolis, Saraswats, Lohanas and Gaurs. An
estimated 10,000-15,000 babies with thalassemia major are born annually. HbE,
is the variant hemoglobin that significantly contributes to hemoglobinopathies,
especially in West Bengal and North East where the carrier frequency can be as
high as 50%. Sickle cell disease prevalence is variable, with very high
frequency in many tribal communities.
In his comments, Adam Mellick,
Global Product Manager - Hematology, Erba Group, UK, said, “Accepted
world-over for their quality, precision and ease-of-operation, the Erba range
of hematology products will bring about an increase in adoption of automated hematology
testing among Indian diagnostic labs. The range
offers a new wave of high performance and
convenience, making it an ideal choice for every lab. It also provides holistic
solutions for clinical testing for general and targeted diagnostics which is an
added advantage for pediatric and geriatric population. Other unique features
include flagging of abnormal samples, RFID, large colored LCD touch screen,
customizable reporting formats, ability to connect to a Laboratory
Information System (LIS) for result output and the ready-to-use reagents being
cyanide free and environment-friendly. By addressing many challenges that labs
and pathologists face, Transasia is helping healthcare professionals (HCPs)
focus on giving patients the best possible care.”
Added Suresh Vazirani, “As per industry reports in 2018, India's medical devices industry is pegged
at a $5.2 billion (Rs. 35,097.40 crore), most of which is imported. It is
players like Transasia who are at the forefront of changing it and driving Make
in India.”
_______________________________________________________________________________________
About Transasia
Bio-Medicals Ltd. : Founded in 1979, Mumbai-based Transasia
Bio-Medicals Ltd., India’s Leading In-vitro Diagnostics player offers products
and solutions in Biochemistry, Haematology, Coagulation, ESR, Immunology,
Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular
Diagnostics. It provides doctors and patients with reliable, affordable and
innovative Diagnostic Systems, with an impressive installed base of 65,000+
across India. It has a vast network of 250+ service engineers, 400+ sales and
marketing team, 23 zonal offices and 350+ distributors. It is the first Indian
company to manufacture and export blood analyzers and reagents, in the 1990s.
Today, Transasia’s indigenous research has resulted in development of state of
the art, ‘Make in India’ products and technologies, enabling its products to be
among the best in the world. All along its journey
spanning four decades, it has been recognized for its commitment to affordable
healthcare. It has been conferred ‘India Medical Device - Export Company
of the Year’ and the ‘Global Growth Company-2014’ by
the World Economic Forum amongst many others. The Transasia-Erba group is present across USA, UK, Germany, Czech Republic,
France, Italy, Russia and Turkey through various acquisitions.
Transasia-Erba Group’s production sites in India, Czech Republic and USA and
R&D centres in France, UK, India and Czech Republic form a hub for
indigenous manufacturing of world class deliverables. Today, the group serves
millions across 100 countries. For further information, kindly visit www.erbamannheim.com
No comments:
Post a Comment